Skip to main content

Leadership

2016 News Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006
DateTitle  
12/29/16Emergent BioSolutions to Participate in First Quarter 2017 Investor ConferencesDownload PDFPrinter Friendly Version
12/12/16Emergent BioSolutions Receives Health Canada Approval for Botulism AntitoxinDownload PDFPrinter Friendly Version
12/08/16Emergent BioSolutions to Support HHS Anthrax Preparedness Strategy With Up to $1 Billion in BioThrax Deliveries to the Strategic National StockpileDownload PDFPrinter Friendly Version
11/08/16Dr. Kathryn C. Zoon Appointed to Emergent BioSolutions Board of DirectorsDownload PDFPrinter Friendly Version
11/07/16Emergent BioSolutions Reports Third Quarter and Nine Months 2016 Financial ResultsDownload PDFPrinter Friendly Version
11/01/16Emergent BioSolutions to Release Third Quarter 2016 Financial Results and Conduct a Conference Call on November 7, 2016Download PDFPrinter Friendly Version
09/30/16Emergent BioSolutions Provides Update on Status of BioThrax Procurement Contract and Discussions With CDCDownload PDFPrinter Friendly Version
09/30/16Emergent BioSolutions Awarded BARDA Contract for Advanced Development and Delivery of NuThrax, a Next Generation Anthrax Vaccine, Valued at Up to $1.6 BillionDownload PDFPrinter Friendly Version
08/15/16Emergent BioSolutions Receives FDA Approval for Large-Scale Manufacturing of BioThrax in Building 55Download PDFPrinter Friendly Version
08/12/16Emergent BioSolutions Announces Conversion Rate Adjustment to 2.875% Convertible Senior Notes Due 2021 Following Spin-Off of Aptevo TherapeuticsDownload PDFPrinter Friendly Version
08/10/16CDC Exercises Contract Option Valued at $11.6 Million to Further Support Emergent BioSolutions’ Vaccinia Immune GlobulinDownload PDFPrinter Friendly Version
08/04/16Emergent BioSolutions Reports Second Quarter and Six Months 2016 Financial ResultsDownload PDFPrinter Friendly Version
08/01/16Emergent BioSolutions Completes Spin-Off of Aptevo TherapeuticsDownload PDFPrinter Friendly Version
07/21/16Emergent BioSolutions to Release Second Quarter 2016 Financial Results and Conduct a Conference Call on August 4, 2016Download PDFPrinter Friendly Version
07/20/16Emergent BioSolutions Announces Commencement of When Issued Trading of Aptevo Common StockDownload PDFPrinter Friendly Version
07/15/16Emergent BioSolutions Announces Effectiveness of Aptevo Therapeutics Form 10 Registration StatementDownload PDFPrinter Friendly Version
07/15/16Emergent BioSolutions to Implement Stock Repurchase Program for Up to $50 Million of Its Common StockDownload PDFPrinter Friendly Version
07/11/16Emergent BioSolutions’ Board of Directors Approves Spin-Off of Aptevo Therapeutics and Sets Record and Dividend Distribution Dates and Distribution RatioDownload PDFPrinter Friendly Version
06/27/16Emergent BioSolutions Receives BARDA Task Order Valued at Up to $21.9 Million to Develop and Manufacture a Zika VaccineDownload PDFPrinter Friendly Version
06/22/16U.S. Government Issues Solicitation Notices Providing Path to Achieve a Stockpile to Protect 25 Million People Through Procurement of Up to 56.4 Million Doses of Anthrax VaccinesDownload PDFPrinter Friendly Version
06/21/16FDA Completes Pre-Approval Inspection of Emergent BioSolutions’ Large-Scale Manufacturing Facility for BioThraxDownload PDFPrinter Friendly Version
06/17/16FDA Accepts Emergent BioSolutions’ Supplemental Biologics License Application for Large-Scale Manufacturing of BioThrax in Building 55Download PDFPrinter Friendly Version
06/15/16Emergent BioSolutions Receives FDA Orphan Drug Status for BioThrax for Post-Exposure Prophylaxis of Anthrax DiseaseDownload PDFPrinter Friendly Version
05/05/16Emergent BioSolutions Reports First Quarter 2016 Financial ResultsDownload PDFPrinter Friendly Version
05/04/16Emergent Biosolutions to Hold Annual Meeting of Stockholders Thursday May 19, 2016 at 9:00 AM Eastern; Webcast Will Be AvailableDownload PDFPrinter Friendly Version
04/26/16Emergent Biosolutions to Participate in the Bank of America Merrill Lynch Healthcare Conference in May 2016Download PDFPrinter Friendly Version
04/21/16Emergent BioSolutions to Release First Quarter 2016 Financial Results and Conduct a Conference Call on May 5, 2016Download PDFPrinter Friendly Version
04/20/16Emergent BioSolutions Presents Preclinical Data on ES425 a Bispecific Immunotherapeutic Protein for Triple-Negative Breast CancerDownload PDFPrinter Friendly Version
04/18/16Emergent BioSolutions Submits sBLA for FDA Approval of Large-Scale Manufacturing of BioThrax in Building 55Download PDFPrinter Friendly Version
04/15/16Emergent BioSolutions Announces Filing of Form 10 Registration Statement for Its Planned Spin-Off of Its Biosciences Business Aptevo TherapeuticsDownload PDFPrinter Friendly Version
03/30/16Emergent BioSolutions to Participate in Needham & Company’s 15th Annual Healthcare Conference in April 2016Download PDFPrinter Friendly Version
02/25/16Emergent BioSolutions Reports Fourth Quarter and Twelve Months 2015 Financial Results and Reaffirms 2016 OutlookDownload PDFPrinter Friendly Version
02/17/16Emergent BioSolutions’ Emergard Auto-Injector Platform for Nerve Agent Antidote Delivery Selected by U.S. Department of Defense and Battelle for Testing and DevelopmentDownload PDFPrinter Friendly Version
02/11/16Emergent BioSolutions to Release Fourth Quarter and Full Year 2015 Financial Results and Conduct a Conference Call on February 25, 2016Download PDFPrinter Friendly Version
01/21/16Emergent BioSolutions Announces Executive Management Team of New Spin-Off Company Aptevo TherapeuticsDownload PDFPrinter Friendly Version
01/11/16Emergent BioSolutions Announces Preliminary 2015 Financial Results, Provides 2016 Financial Outlook, and Outlines New Five-Year (2016-2020) Strategic Growth PlanDownload PDFPrinter Friendly Version
01/10/16Emergent BioSolutions Receives Favorable IRS Private Letter Ruling in Connection With its Planned Biosciences Business Spin-OffDownload PDFPrinter Friendly Version